echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > J Allergy Clin Immunol: Rusolitini has shown positive results in the treatment of patients with severe COVID-19.

    J Allergy Clin Immunol: Rusolitini has shown positive results in the treatment of patients with severe COVID-19.

    • Last Update: 2020-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Existing research evidence suggests that Janus-related kinase (JAK) inhibitors are therapeutic targets worthy of rapid study.
    study evaluated the efficacy and safety of JAK1/2 inhibitor Rusolitinib in the treatment of coronavirus disease in 2019.
    conducted a forward-looking, multi-center, single-blind, randomized controlled Phase II trial in patients with severe COVID-19.
    43 patients were randomly assigned (1:1) to rusolitinib joint standard care treatment (22 patients) or to a placebo group (21 patients) based on standard care treatment.
    excluded 2 patients from the Rusolitinie group (1 did not meet the criteria and 1 withdrew their consent), they were eventually included in 20 patients in the intervention group and 21 patients in the control group.
    results, in patients with COVID-19 severity, although the clinical improvement of Rusolitini recipients was faster, the treatment of Rusolitini combined standard care was not associated with clinical improvement in severe patients.
    results of computer fault scans showed that 18 (90%) patients in the Rusolitini group improved on the 14th day, compared with 13 patients (61.9%) in the control group (P.0495).
    three patients in the control group died of respiratory failure, with a total mortality rate of 14.3 per cent over 28 days, and none in the Rusolitini group died.
    rusolitinium is well resistant, low toxicity and has no new safety warning signs.
    levels of seven cytokines in the Rusolitinie group were significantly lower than in the control group.
    , although no statistical differences were observed, the clinical improvement of Rusolitini recipients was faster.
    significant improvement in chest computer litacle scans in the Rusolitinie group, faster recovery of lymphocyte reduction and good side effects are encouraging and useful for future trials to test Rusolitinini's efficacy in a larger population.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.